External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Last month the Therapeutic Goods Administration (TGA) upgraded IDT’s sterile manufacturing licence, allowing it to manufacture and release injectable medicines for clinical trials in Australia and overseas.</li><li>We view this is an important step towards the company’s goal of generating meaningful revenue from sterile injectable drugs, which is intended to put it on the pathway to a return to profitability.</li><li>The company notes that it already has a pipeline of potential sterile manufacturing contracts that stands at over $6m.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Last month the Therapeutic Goods Administration (TGA) upgraded IDT’s sterile manufacturing licence, allowing it to manufacture and release injectable medicines for clinical trials in Australia and overseas.We view this is an important step towards the company’s goal of generating meaningful revenue from sterile injectable drugs, which is intended to put it on the pathway to a return to profitability.The company notes that it already has a pipeline of potential sterile manufacturing contracts that stands at over $6m.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IDT Australia (IDT) - Sterile Manufacturing Licence Opens Sales Opportunities